SCIO Scios Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc.

SCIO 0.01000

0.0%

Aug 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (961)	12/30/1998 4:57:00 PM
From: ubrx	Read Replies (1) of 1477

Miljenko, Thanks for the quick response. I agree that Natrecor's indications are likely to be expanded if approval occurs for the indication of Acute CHF. A chronic CHF treatment of subcutaneous injections might be the next trial. The Abbott/Biosite/Scios BNP diagnostic products have potential to be big winners as well. As for Fiblast, I hope you are correct that Scios is on the forefront of research. Those German trials that Jimmy D. referred to lead me to believe that others are ahead of us in human testing for CAD. Perhaps Scios is just being quiet until they have even more compelling data. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next